| Overview |
| bs-11322R-Cy7 |
| Membralin/C19orf6 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Zebrafish |
| Human, Mouse, Rat, Dog, Cow, Sheep, Pig |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Membralin |
| 161-260/620 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| ASBABP1; C19orf6; MGC4022; R32184_3; aspecic BCL2 ARE-binding protein 1; C19orf6; chromosome 19 open reading frame 6; MBRL; MBRL_HUMAN. |
| The gene encoding human Membralin, C19orf6, localizes to chromosome 19p13.3. It contains 11 exons, which encode at least two splice variants in human cancer. Membralin is a multi-pass membrane protein and exists either as a long or short form. The long form of Membralin comprises all 11 exons, while the short form contains all exons except exon 10. Expression of different Membralin isoforms depends on tissue type. The long form is expressed in ovarian and colorectal carcinomas, whereas the short form is expressed in breast or pancreatic carcinomas. Because Membralin expression in ovarian carcinomas is highest in serous carcinomas as compared to surface epithelium carcinomas, expression of Membralin may be useful as a novel tumor-associated marker in ovarian serous carcinomas. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz